• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    6/5/23 9:06:45 AM ET
    $AMED
    $BJDX
    $BLPH
    $BPMC
    Medical/Nursing Services
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AMED alert in real time by email

    Gainers

    • Timber Pharmaceuticals (AMEX:TMBR) shares increased by 87.9% to $2.8 during Monday's pre-market session. The company's market cap stands at $8.5 million.
    • Evaxion Biotech (NASDAQ:EVAX) shares moved upwards by 43.24% to $2.12. The market value of their outstanding shares is at $56.0 million. As per the press release, Q1 earnings came out 3 days ago.
    • BiondVax Pharmaceuticals (NASDAQ:BVXV) stock moved upwards by 27.64% to $2.17. The company's market cap stands at $7.1 million.
    • CohBar (NASDAQ:CWBR) stock rose 20.27% to $3.44. The market value of their outstanding shares is at $9.9 million.
    • Amedisys (NASDAQ:AMED) stock increased by 15.74% to $91.98. The company's market cap stands at $2.9 billion.
    • Day One Biopharmaceutical (NASDAQ:DAWN) shares increased by 14.7% to $15.6. The market value of their outstanding shares is at $1.1 billion.

    Losers

    • Bellerophon Therapeutics (NASDAQ:BLPH) stock declined by 79.3% to $1.46 during Monday's pre-market session. The company's market cap stands at $15.2 million.
    • Mallinckrodt (AMEX:MNK) shares fell 23.08% to $1.88. The market value of their outstanding shares is at $24.8 million.
    • Cibus (NASDAQ:CBUS) shares fell 19.64% to $19.61. The company's market cap stands at $19.5 million.
    • Castle Biosciences (NASDAQ:CSTL) stock decreased by 16.42% to $19.0. The market value of their outstanding shares is at $507.1 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) shares fell 13.73% to $0.21. The market value of their outstanding shares is at $4.3 million.
    • Blueprint Medicines (NASDAQ:BPMC) stock fell 9.76% to $52.54. The market value of their outstanding shares is at $3.1 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMED alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMED
    $BJDX
    $BLPH
    $BPMC

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Day One Biopharmaceuticals Inc.
    $DAWN
    1/13/2026$34.00Buy
    TD Cowen
    Day One Biopharmaceuticals Inc.
    $DAWN
    8/19/2025$25.00Overweight
    Piper Sandler
    Blueprint Medicines Corporation
    $BPMC
    6/2/2025$129.00Outperform → Neutral
    Wedbush
    Blueprint Medicines Corporation
    $BPMC
    3/20/2025$100.00Equal-Weight
    Morgan Stanley
    Blueprint Medicines Corporation
    $BPMC
    3/18/2025Outperform
    Wolfe Research
    Blueprint Medicines Corporation
    $BPMC
    3/17/2025$135.00Buy
    Jefferies
    Blueprint Medicines Corporation
    $BPMC
    3/7/2025$150.00Sector Outperform
    Scotiabank
    More analyst ratings

    $AMED
    $BJDX
    $BLPH
    $BPMC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Merendino Lauren converted options into 15,162 shares and sold $67,448 worth of shares (5,814 units at $11.60), increasing direct ownership by 18% to 60,157 units (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    2/18/26 5:18:49 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gen Counsel & Secretary Dubow Adam converted options into 16,463 shares and sold $74,188 worth of shares (6,395 units at $11.60), increasing direct ownership by 16% to 72,694 units (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    2/18/26 5:17:40 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO and CFO York Charles N Ii converted options into 23,375 shares and sold $70,359 worth of shares (6,065 units at $11.60), increasing direct ownership by 6% to 312,025 units (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    2/18/26 5:16:10 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMED
    $BJDX
    $BLPH
    $BPMC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen resumed coverage on Day One Biopharmaceuticals with a new price target

    TD Cowen resumed coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $34.00

    1/13/26 8:59:51 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Day One Biopharmaceuticals with a new price target

    Piper Sandler initiated coverage of Day One Biopharmaceuticals with a rating of Overweight and set a new price target of $25.00

    8/19/25 8:33:40 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMED
    $BJDX
    $BLPH
    $BPMC
    SEC Filings

    View All

    SEC Form 10-K filed by Day One Biopharmaceuticals Inc.

    10-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

    2/24/26 4:06:03 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Biopharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

    2/24/26 4:00:37 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    2/20/26 9:54:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $AMED
    $BJDX
    $BLPH
    $BPMC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

    Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

    4/24/24 12:52:43 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMED
    $BJDX
    $BLPH
    $BPMC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

    OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its finan

    2/24/26 4:00:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

    ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share. The Company notes that several recent Schedule 13G filings made by investors

    2/20/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

    FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter clinical validation study in the Journal of the American Academy of Dermatology (JAAD) demonstrating that its AdvanceAD-Tx test can identify patients with moderate-to-severe atopic dermatitis (AD) who are significantly more likely to achieve greater and faster clinical responses when treated with a Janus kinase inhibitor (JAKi) compared to T helper type 2 (Th2)-targeted therapies.1 "Atopic dermatitis can look similar on the surface, but the biology driving the

    2/19/26 5:46:40 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $AMED
    $BJDX
    $BLPH
    $BPMC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

    4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    12/14/23 4:17:42 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

    4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    12/14/23 4:16:33 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Ai Day1 Llc bought $14,978,327 worth of shares (1,475,454 units at $10.15) (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    10/20/23 4:02:31 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMED
    $BJDX
    $BLPH
    $BPMC
    Leadership Updates

    Live Leadership Updates

    View All

    Cibus Announces the Election of Craig Wichner to Board of Directors

    SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the election of Craig Wichner to its Board of Directors. Mr. Wichner will also serve as a member of the Board's current Strategy Committee. "Craig brings an exceptional combination of financial acumen, strategic discipline, and industry insight to the Cibus Board," said Mark Finn, Chairman of the Board of Cibus. "As Cibus prepares for anticipated commercial scaling of our trait platform, Craig's expertise in sustainable growth and capital strategy in agriculture will be instrumental in strengthening our

    11/11/25 7:00:00 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

    Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion's strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her role as Chief Scientific OfficerSeasoned life science executive Jens Bitsch-Norhave will join as observer and advisor to the Board of Directors with the intention of seeking election at the

    10/27/25 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cibus Announces the Election of Kimberly A. Box to Board of Directors

    SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company developing and licensing advanced plant traits that enable higher yields, lower input costs, and more sustainable farming, today announced the election of Kimberly A. Box to its Board of Directors. "Kim brings to Cibus extensive leadership experience in technology and commercialization that will be invaluable as we sharpen our strategic commercialization efforts," said Mark Finn, Cibus Chairman. "Her understanding of market dynamics and experience in guiding innovation into scalable businesses will strengthen our strategic governance as we continue to drive long-term value c

    9/25/25 4:05:00 PM ET
    $CBUS
    $MGRC
    Agricultural Chemicals
    Industrials
    Diversified Commercial Services
    Consumer Discretionary

    $AMED
    $BJDX
    $BLPH
    $BPMC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/14/24 4:40:39 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

    SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/14/24 4:30:11 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMED
    $BJDX
    $BLPH
    $BPMC
    Financials

    Live finance-specific insights

    View All

    Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

    OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its finan

    2/24/26 4:00:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

    BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2025. Live audio of the webcast will be accessible by visiting the Events section of Day One's Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days follo

    2/10/26 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

    FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/483643109, or via the webcast link on the Investor Relations page of the Company's website: htt

    2/5/26 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care